©Johnson & Johnson Consumer Inc. 2017. All rights reserved. RHINOCORT ® is a licensed trademark of AstraZeneca AB. The third-party trademarks used herein are registered trademarks of their respective owners and not Johnson & Johnson Consumer Inc. This site is published by Johnson & Johnson Consumer Inc., McNeil Consumer Healthcare Division, which is solely responsible for its contents. This website is intended for . healthcare professionals only. Questions or comments? Call our Customer Care Center for Healthcare Professionals at 1-866-948-6883 , Monday through Friday, 9:00 am to 4:30 pm ET.
Acute overdosage by intranasal administration is unlikely since ipratropium bromide is not well absorbed systemically after intranasal or oral administration. Following administration of a 20 mg oral dose (equivalent to ingesting more than two bottles of Atrovent® (ipratropium bromide) Nasal Spray %) to 10 male volunteers, no change in heart rate or blood pressure was noted. Following a 2 mg intravenous infusion over 15 minutes to the same 10 male volunteers, plasma ipratropium concentrations of 22-45 ng/mL were observed (>100 times the concentrations observed following intranasal administration). Following intravenous infusion these 10 volunteers had a mean increase of heart rate of 50 bpm and less than 20 mmHg change in systolic or diastolic blood pressure at the time of peak ipratropium levels.
Any communications or information you transmit to this website by electronic mail or otherwise to Chattem shall be treated as non-confidential and non-proprietary. Although we welcome your comments and feedback with respect to this website or any of our products, we are not seeking and do not review any unsolicited ideas, suggestions or materials related to the development, design, manufacture or marketing of our products or the conduct of our business. This policy is intended to avoid confusion about the ownership of new ideas and concepts and to help protect you. By sending us any proposed ideas or other such information, you agree to transfer to Chattem all of your rights and interests in such proposed intellectual property, ideas and information. You further agree that any ideas, concepts or know-how that you or individuals acting on your behalf provide to Chattem can be used, reproduced, transmitted, disclosed or published by Chattem or its affiliates without restriction or compensation.